Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: A qualitative preference study of patients and parents.
<h4>Objectives</h4>Duchenne muscular dystrophy (DMD) is a rare neuromuscular disorder that causes progressive weakness and early death. Gene therapy is an area of new therapeutic development. This qualitative study explored factors influencing parents' and adult patients' prefe...
Main Authors: | Holly Landrum Peay, Ryan Fischer, Janice P Tzeng, Sharon E Hesterlee, Carl Morris, Amy Strong Martin, Colin Rensch, Edward Smith, Valeria Ricotti, Katherine Beaverson, Hannah Wand, Carol Mansfield |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0213649 |
Similar Items
-
Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best–worst scaling experiment in caregivers and adult patients
by: Ryan S. Paquin, et al.
Published: (2019-05-01) -
Theragnosis for Duchenne Muscular Dystrophy
by: Leonela Luce, et al.
Published: (2021-06-01) -
Sources of variation in estimates of Duchenne and Becker muscular dystrophy prevalence in the United States
by: Nedra Whitehead, et al.
Published: (2023-03-01) -
Utrophin in the therapy of Duchenne Muscular Dystrophy
by: Potter, A, et al.
Published: (2006) -
Regenerative biomarkers for Duchenne muscular dystrophy
by: Guiraud, S, et al.
Published: (2019)